Dublin, Ireland, November 26, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced that Inflection Biosciences was selected as a finalist to present at the 13th Tech Tour Contest Final 2019 taking place on 9-10 December 2019 in Essen, Germany.
The Final will present 175+ European innovative companies in the high-technology sectors to an international audience of investors, key corporates and innovation experts.
About the Tech Tour Contest Final:
150+ investors and corporates175+ presenting companies18 presentation sessions sector focused3 Award Winners350+ attendees 14.3 € billon value of strategic deals of Tech Tour presenting companies over the last 7 yearsOver 10 M assets under management in total of participating funds
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com